Advancing novel, small molecule treatments targeting epigenetic mechanisms in tumor and immune cells for the benefit of patients

Constellation Pharmaceuticals (NASDAQ: CNST) is a clinical-stage biopharmaceutical company developing novel small molecule therapies based on its pioneering research in cancer epigenetics. With a decade of experience in the field, the company has an unparalleled understanding of how epigenetic regulators modulate gene expression in cancer cells and in the tumor and immune microenvironment. Constellation is translating these insights to advance the company’s two lead clinical programs, CPI-1205 and CPI-0610, and in novel targets for which cancer epigenetics may help overcome resistance mechanisms to currently available treatment options.

Year Invested: 2008
Location: Cambridge, Mass.

Recent News

November 29, 2018
Constellation Pharmaceuticals to Present at BMO Healthcare Conference

November 29, 2018
Constellation Pharmaceuticals Appoints Patrick Trojer, Ph.D., as Chief Scientific Officer

November 15, 2018
Constellation Pharmaceuticals Highlights EZH2 Inhibition Program in Prostate Cancer at Biomedical Conference

Read More News

Associated Team Members

Robert Tepper, M.D.

Neil Exter

Craig Muir
Partner/Chief Technology Officer